Biopharmaceutical Firm Gilead Takes 50,000 Sq Ft at One Triton Square

Why It Matters

The lease expands Gilead’s UK footprint, reinforcing London’s role as a biotech hub and boosting the asset’s revenue potential. It also signals robust investor confidence in life‑science real estate.

Key Takeaways

• Gilead leases 50,000 sq ft at One Triton Square.
• Building now 77% occupied or under offer.
• Space includes labs, flexible offices, event facilities.
• Prime London location boosts Gilead’s UK footprint.
• Landlords expect higher rents and strong investment returns.

Pulse Analysis

The decision by Gilead Sciences to secure 50,000 sq ft at One Triton Square underscores the biotech giant’s strategic push to deepen its presence in Europe. As a developer of antiviral and oncology therapies, Gilead benefits from proximity to London’s dense network of research institutions, talent pools, and regulatory bodies. The new footprint will likely house both corporate functions and laboratory work, aligning with the company’s broader effort to accelerate drug pipelines post‑pandemic. In a market where location can influence partnership opportunities, the move signals confidence in the UK’s biotech ecosystem.

One Triton Square, completed in October 2025, offers more than 300,000 sq ft of sustainable, purpose‑built space, including fitted laboratories, flexible workstations, and shared event venues. British Land and Royal London Asset Management report that the building is now 77 % let or under offer, with five deals totaling 71,000 sq ft signed before Gilead’s tenancy. The high occupancy rate reflects strong demand for premium, science‑ready environments in central London, allowing landlords to command strategic surrender premiums and secure superior rental yields. The development’s green credentials further enhance its appeal to ESG‑focused tenants.

The Gilead lease highlights a broader shift as pharmaceutical firms prioritize flexible, lab‑integrated office solutions to accelerate R&D cycles. London’s core districts, with their transport links and talent density, are becoming hotbeds for such hybrid spaces, driving up valuations for assets like One Triton Square. Investors are responding by allocating more capital to real‑estate funds that specialize in life‑science properties, expecting robust, inflation‑linked returns. As the sector continues to grow, occupancy pressures may tighten, prompting developers to embed more advanced infrastructure and sustainability features to stay competitive.